Stacey Stein, MD
Medical Oncology · New Haven, CTNPI 1285824706
Payments from drug & device makers
Across 636 payments — averaging $3762.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$831K
- Merck$749K
- Macrogenics, Inc.$283K
- E.r. Squibb & Sons, L.L.C.$164K
- Halozyme Inc$158K
- AstraZeneca$107K
- plus $100K from 17 others
Across 5 payments — averaging $2319.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$8K
- Macrogenics, Inc.$2K
- Genentech, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 172 | $831,309 |
| Merck | 141 | $748,757 |
| Macrogenics, Inc. | 18 | $283,269 |
| E.r. Squibb & Sons, L.L.C. | 9 | $164,124 |
| Halozyme Inc | 181 | $158,119 |
| AstraZeneca | 17 | $106,781 |
| Incyte Corporation | 17 | $19,611 |
| Bayer | 7 | $14,539 |
| Exelixis Inc. | 12 | $11,239 |
| AbbVie | 9 | $11,037 |
| Regeneron | 4 | $7,124 |
| Partner Therapeutics, Inc. | 15 | $5,966 |
| F. Hoffmann-la Roche AG | 11 | $5,753 |
| Eisai Inc. | 8 | $4,809 |
| Ipsen Biopharmaceuticals, Inc | 2 | $4,496 |
| Astrazeneca UK Limited | 2 | $4,453 |
| Jazz Pharmaceuticals Inc. | 2 | $3,120 |
| Boston Scientific | 1 | $2,275 |
| Guerbet LLC | 2 | $2,161 |
| Genentech USA, Inc. | 3 | $1,793 |
| GSK | 1 | $1,450 |
| Deciphera Pharmaceuticals Inc. | 1 | $525 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $129 |
How this compares
$2,392,838 in reported general payments places this provider in the 80th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New Haven
- Lajos PusztaiNew Haven$23.5M
- Sarah GoldbergNew Haven$17.7M
- Harriet KlugerNew Haven$17.7M
- Daniel PetrylakNew Haven$10M
- Ian KropNew Haven$7.5M
- Anne ChiangNew Haven$5.8M
- Noffar BarNew Haven$5.4M
- Scott GettingerNew Haven$5.1M
- Jill LacyNew Haven$3.5M
- Aarti BhatiaNew Haven$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.